Zanubrutinib is a BTK inhibitor reported to be effective for B‐cell lymphomas with MYD88 and CD79b mutations, double expression of MYC and BCL2/BCL6, and CD5 expression.33, 34, 35. This evidence concerns the gene MYD88 and B-cell non-Hodgkin lymphoma.